Checkmate Pharmaceuticals (Checkmate Pharmaceuticals) Market Cap : $231.40 Mil (As of Jun. 06, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Checkmate Pharmaceuticals Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Checkmate Pharmaceuticals's share price for the quarter that ended in Mar. 2022 was $3.19. Checkmate Pharmaceuticals's Shares Outstanding (EOP) for the quarter that ended in Mar. 2022 was 21.63 Mil. Therefore, Checkmate Pharmaceuticals's market cap for the quarter that ended in Mar. 2022 was $69.00 Mil.

Checkmate Pharmaceuticals's quarterly market cap declined from Sep. 2021 ($85.86 Mil) to Dec. 2021 ($62.08 Mil) but then increased from Dec. 2021 ($62.08 Mil) to Mar. 2022 ($69.00 Mil).

Checkmate Pharmaceuticals's annual market cap increased from Dec. 2019 ($0.00 Mil) to Dec. 2020 ($314.57 Mil) but then declined from Dec. 2020 ($314.57 Mil) to Dec. 2021 ($62.08 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Checkmate Pharmaceuticals's Enterprise Value for Today is $171.37 Mil.

Checkmate Pharmaceuticals Market Cap Historical Data

The historical data trend for Checkmate Pharmaceuticals's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Checkmate Pharmaceuticals Market Cap Chart

Checkmate Pharmaceuticals Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Market Cap

314.57

62.08

Checkmate Pharmaceuticals Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22
Market Cap	Get a 7-Day Free Trial									262.46	128.89	85.86	62.08	69.00

Competitive Comparison of Checkmate Pharmaceuticals's Market Cap

For the Biotechnology subindustry, Checkmate Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Checkmate Pharmaceuticals's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Checkmate Pharmaceuticals's Market Cap distribution charts can be found below:

* The bar in red indicates where Checkmate Pharmaceuticals's Market Cap falls into.

Checkmate Pharmaceuticals Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Checkmate Pharmaceuticals's Market Cap for the fiscal year that ended in Dec. 2021 is calculated as

Market Cap (A: Dec. 2021 )	=	Share Price (A: Dec. 2021 )	*	Shares Outstanding (EOP) (A: Dec. 2021 )
	=	$2.87	*	21.6306
	=	$62.08

Checkmate Pharmaceuticals's Market Cap for the quarter that ended in Mar. 2022 is calculated as

Market Cap (Q: Mar. 2022 )	=	Share Price (Q: Mar. 2022 )	*	Shares Outstanding (EOP) (Q: Mar. 2022 )
	=	$3.19	*	21.6306
	=	$69.00

Checkmate Pharmaceuticals (NAS:CMPI) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.

Checkmate Pharmaceuticals Market Cap Related Terms

Thank you for viewing the detailed overview of Checkmate Pharmaceuticals's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.

Checkmate Pharmaceuticals (Checkmate Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Checkmate Pharmaceuticals Inc (NAS:CMPI) » Definitions » Market Cap

Comparable Companies

Traded in Other Exchanges

N/A

Address

245 Main Street, 2nd Floor, Cambridge, MA, USA, 02142

Website

https://www.checkmatepharma.com

Checkmate Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing its proprietary technology to harness the power of the immune system to combat cancer.

Executives

Venbio Global Strategic Fund Ii L.p.	10 percent owner	1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Alan Bash	director, officer: Chief Executive Officer	C/O CHECKMATE PAHRMACEUTICALS, INC. 245 MAIN STREET 2ND FLOOR CAMBRIDGE MA 02142
Novo Holdings A/s	10 percent owner	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Jon Marc Wigginton	director	9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Joy Yan	director	10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Arthur M Krieg	director, officer: Chief Scientific Officer	C/O CHECKMATE PHARMACEUTICALS, INC., 245 MAIN STREET, 2ND FLOOR, CAMBRIDGE MA 02142
Robert Dolski	officer: Chief Financial Officer	C/O CHECKMATE PHARMACEUTICALS, INC. 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142
Barry Labinger	director, officer: President and CEO	C/O CHECKMATE PHARMACEUTICALS, INC., 245 MAIN STREET, 2ND FLOOR, CAMBRIDGE MA 02142
Peter Colabuono	director	C/O DECHENG CAPITAL 3000 SAND HILL ROAD, BUILDING 2, STE 110 MENLO PARK CA 94025
Oren Isacoff	director	C/O LONGITUDE CAPITAL 2740 SAND HILL ROAD, 2ND FLOOR MENLO PARK CA 94025
Karen Brennan	officer: Chief Operating Officer	C/O CHECKMATE PHARMACEUTICALS, INC. 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142
Kleem Chaudhary	officer: Chief Business Officer	C/O CHECKMATE PHARMACEUTICALS, INC. 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142
Venbio Global Strategic Gp Ii, L.p.	10 percent owner	1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Venbio Global Strategic Gp Ii, Ltd.	10 percent owner	1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Nilesh Kumar	director	C/O MILESTONE PHARMACEUTICALS, INC., 1111 DR. FREDERIK-PHILIPS BLVD, STE 420, MONTR?AL A8 H4M 2X6